Welcome to our dedicated page for SEELOS THERAPEUTICS news (Ticker: SEEL), a resource for investors and traders seeking the latest updates and insights on SEELOS THERAPEUTICS stock.
Seelos Therapeutics, Inc. (Nasdaq: SEEL) is a clinical-stage biopharmaceutical company committed to developing and commercializing novel therapeutic solutions for central nervous system (CNS) disorders and rare ailments. Based in New York, the company's primary focus is on innovative technologies aimed at treating conditions like major depressive disorder (MDD), post-traumatic stress disorder (PTSD), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and more.
Key developments in Seelos' pipeline include:
- SLS-002: An intranasal racemic ketamine targeting acute suicidal ideation and behavior in MDD and PTSD patients. This promising treatment has shown significant efficacy in Phase II trials, with plans for Phase III trials underway.
- SLS-005: A protein stabilizer for treating Sanfilippo syndrome and ALS. Recent trials in collaboration with the HEALEY ALS Platform have highlighted its potential benefits, even though some endpoints were not statistically significant.
- SLS-006: A partial dopamine agonist developed for PD patients, emphasizing symptom relief and improved quality of life.
- Preclinical Programs: These include SLS-007, an anti-alpha-synuclein inhibitor for PD; SLS-008, targeting chronic inflammation in asthma and pediatric orphan indications; and SLS-004 and SLS-010 for PD and narcolepsy, respectively.
Seelos Therapeutics actively engages in various clinical trials and collaborations to advance its therapeutic offerings. The company recently announced public offerings and strategic financial maneuvers to support its robust pipeline, including offerings totaling approximately $10.65 million in gross proceeds. These funds are earmarked for advancing Seelos' clinical programs and general corporate purposes.
Committed to addressing unmet medical needs, Seelos Therapeutics is poised to make significant contributions to the biopharmaceutical landscape, with a keen focus on CNS disorders and rare diseases.
Seelos Therapeutics (Nasdaq: SEEL) announced the initiation of its Expanded Access Program (EAP) for patients with Amyotrophic Lateral Sclerosis (ALS) who do not qualify for existing clinical trials. Funded by a NINDS grant under the ACT for ALS, the program aims to enroll 70 patients over 24 weeks to evaluate SLS-005. This investigational treatment is designed to stabilize proteins and activate autophagy. The CEO expressed gratitude for community support and emphasized the importance of the EAP for ALS patients lacking other therapy options. The ongoing Phase II/III study on the HEALEY ALS Platform will run concurrently.
Seelos Therapeutics (Nasdaq: SEEL) provided an update on March 29, 2023, focusing on its clinical programs. The company is temporarily pausing patient enrollment in the SLS-005-302 study for spinocerebellar ataxia type 3 (SCA3) due to financial considerations, although current participants will continue in the study. Seelos aims to concentrate resources on the SLS-002 study for Acute Suicidal Ideation and Behavior with expected data readout by Q3 2023, and the SLS-005 study for ALS data in late 2023. Seelos' corporate structure allows for strategic flexibility while extending its cash runway for upcoming data readouts.
Seelos Therapeutics, Inc. (NASDAQ: SEEL) announced a registered direct offering of 12,059,298 shares of common stock and warrants for 26,750,000 shares at a price of
Seelos Therapeutics, Inc. (NASDAQ: SEEL) announced its participation in the 43rd Annual Cowen Health Care Conference happening in Boston, Massachusetts from March 6-8, 2023. CEO Raj Mehra and senior management will host meetings during the event. Seelos is focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio targeting conditions like Acute Suicidal Ideation in Major Depressive Disorder and various neurodegenerative diseases including ALS and Huntington’s disease. For more details, visit their website.
FAQ
What is the current stock price of SEELOS THERAPEUTICS (SEEL)?
What is the market cap of SEELOS THERAPEUTICS (SEEL)?
What does Seelos Therapeutics, Inc. do?
What are the key products in Seelos Therapeutics' pipeline?
What recent achievements has Seelos Therapeutics made?
How does SLS-002 work?
What is the financial status of Seelos Therapeutics?
Who are Seelos Therapeutics' key partners?
What is SLS-005, and what does it treat?
What is the status of SLS-005 in clinical trials?
How is Seelos Therapeutics funded?
What are the future plans for Seelos Therapeutics?
